Literature DB >> 6131357

Properties of a selective kappa agonist, U-50,488H.

R A Lahti, P F VonVoigtlander, C Barsuhn.   

Abstract

U-50,488H has been shown to be a naloxone antagonizable analgesic in rodents. However, the dose of naloxone needed for antagonism is higher than it is for morphine. U-50,488H does not produce physical dependence; however it does produce tolerance upon chronic administration. U-50,488H is cross tolerant with bremazocine but not with morphine. Monkeys trained to discriminate ethylketocyclazocine (EKC) from saline show a complete generalization to U-50,488H but not to morphine. The evaluation of U-50,488H in 3H-EKC site-selective binding indicated that U-50,488H has a high affinity for the kappa receptor (Ki = 114 nM) and a low affinity for the mu receptor (Ki = 6100 nM). The ratio of Ku/Kk was 0.08 for morphine, 0.4 for dynorphin, and 53.5 for U-50,488H. The data suggest that U-50,488H is a selective agonist at the opioid kappa receptor.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6131357     DOI: 10.1016/0024-3205(82)90132-1

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  23 in total

Review 1.  The role of kappa-opioid receptor activation in mediating antinociception and addiction.

Authors:  Yu-hua Wang; Jian-feng Sun; Yi-min Tao; Zhi-qiang Chi; Jing-gen Liu
Journal:  Acta Pharmacol Sin       Date:  2010-08-23       Impact factor: 6.150

2.  Dynorphin A decreases voltage-dependent calcium conductance of mouse dorsal root ganglion neurones.

Authors:  R L Macdonald; M A Werz
Journal:  J Physiol       Date:  1986-08       Impact factor: 5.182

Review 3.  The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse.

Authors:  Sunmee Wee; George F Koob
Journal:  Psychopharmacology (Berl)       Date:  2010-03-30       Impact factor: 4.530

4.  Evaluation of the effects of opioid agonists and antagonists under a delayed matching-to-sample procedure in pigeons.

Authors:  M Picker; C A Massie; L A Dykstra
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

5.  Disruption of the kappa-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective kappa-agonist U-50,488H and attenuates morphine withdrawal.

Authors:  F Simonin; O Valverde; C Smadja; S Slowe; I Kitchen; A Dierich; M Le Meur; B P Roques; R Maldonado; B L Kieffer
Journal:  EMBO J       Date:  1998-02-16       Impact factor: 11.598

6.  The histamine-releasing effect of dynorphin and other peptides possessing Arg-Pro sequences.

Authors:  A Sydbom; L Terenius
Journal:  Agents Actions       Date:  1985-04

7.  Bremazocine differentially antagonizes responses to selective mu and delta opioid receptor agonists in rat hippocampus.

Authors:  T V Dunwiddie; K J Johnson; W R Proctor
Journal:  Br J Pharmacol       Date:  1987-07       Impact factor: 8.739

8.  A cell-based, high-throughput homogeneous time-resolved fluorescence assay for the screening of potential κ-opioid receptor agonists.

Authors:  Yue Wang; Ming Yan; Guang-Yao Zheng; Ling He; Huan Yang
Journal:  Acta Pharmacol Sin       Date:  2014-06-16       Impact factor: 6.150

9.  kappa-opioid regulation of neuronal activity in the rat supraoptic nucleus in vivo.

Authors:  C H Brown; M Ludwig; G Leng
Journal:  J Neurosci       Date:  1998-11-15       Impact factor: 6.167

10.  Cardiovascular actions of the kappa-agonist, U-50,488H, in the absence and presence of opioid receptor blockade.

Authors:  M K Pugsley; W P Penz; M J Walker; T M Wong
Journal:  Br J Pharmacol       Date:  1992-03       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.